Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2019-10-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating Genetic Status in Patients Presenting to Clinic
NCT05911932
Longitudinal Study of Neurodegenerative Disorders
NCT03333200
Genetics of Familial and Sporadic ALS
NCT00821132
Identification of New FTLD Genes
NCT02363062
Study of Inherited Neurological Disorders
NCT00004568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild Cognitive Impairment
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Alzheimer's Disease
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Dementia with Lewy Bodies
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Frontotemporal Lobar Dementia
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Parkinson's Disease with Dementia
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Transient Epileptic Amnesia
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Temporal Lobe Epilepsy
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Spinocerebellar Ataxia
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
HIV-Associated Neurocognitive Disorder
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Amyotrophic Lateral Sclerosis
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Primary Lateral Sclerosis
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuraceq
Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18 or older
3. Reliable informant with frequent contact with participant
4. Mini Mental State Exam (MMSE) ≥15 AND/OR Clinical Dementia Rating (CDR) less than 2
5. Able to undergo extensive psychometric testing
Exclusion Criteria
* Past or present diagnosis of Korsakoff's syndrome
* Alcohol or substance abuse preceding dementia \& still present within 5 years of onset
* Present untreated vitamin B12 or folate deficiency
* Present untreated hypothyroidism
* Past or present head trauma with persistent deficits
* Present untreated syphilis
* Past or present multiple sclerosis or another neuro-inflammatory disorder
* Past or present vascular or multi-infarct dementia
* Past or present diagnosis of huntington's disease
* Past or present normal pressure hydrocephalus
* Past or present central nervous system (CNS) lesions deemed to be clinically significant
* Unresolved or present subdural hematoma
* Past or present Ischemic Vascular Dementia
* Past or present intracerebral hemorrhage
* Present systematic liver disease
* Present renal insufficiency requiring dialysis
* Present encephalitis or meningitis
* Present anxiety disorder (not due to dementia and requiring medication more than 3x per week)
* Present severe periventricular white matter disease or greater than grade 4 white matter lesions
* Present lacunar infarcts deemed to clinically significant
* Present cortical stroke
* Present respiratory condition requiring oxygen
2. Present significant systemic medical illness, such as cancer requiring chemotherapy or end stage cardiac insufficiency
3. Present inability to safely scan in an MRI
4. Present pregnancy or lactation - Female participants will be asked to confirm that they are not pregnant and do not plan to become pregnant.
5. Present current medication likely to affect CNS functions:
* Benzodiazepines (no triazolam, but other short-acting benzodiazepines are OK)
* Antidepressant therapy with amitriptyline or doxepin or tx not stable during past year
* Neuroleptics in the phenothiazine and haloperidol families (atypicals OK)
* Narcotics (codeine is OK, but hold 24 hours before neuropsychological testing)
* Anti-seizure medication outside of therapeutic ranges
* Antihistamines (\> 3x per week; hold 24 hours before neuropsychological testing)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith Vossel, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00007108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.